China Feihe Limited (CFEIY)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CFEIY steht fuer China Feihe Limited, ein Consumer Defensive-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 50/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026China Feihe Limited (CFEIY) Konsumgueeter-Geschaeftsueberblick
China Feihe Limited is a leading infant milk formula producer in China, offering a range of nutritional products through a widespread distribution network encompassing both online platforms and traditional retail outlets, positioning it within the competitive packaged foods sector.
Investmentthese
China Feihe Limited presents a compelling investment case based on its established market position in the Chinese infant milk formula industry and its extensive distribution network. With a P/E ratio of 11.61 and a profit margin of 13.6%, the company demonstrates solid profitability. A dividend yield of 7.25% offers an attractive return to investors. Growth catalysts include expanding product lines and increasing penetration in lower-tier cities. However, investors may want to evaluate potential risks such as regulatory changes in the infant formula industry and competition from both domestic and international players. The company's beta of 0.56 suggests lower volatility compared to the overall market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $4.52 billion, reflecting its significant presence in the Chinese infant milk formula market.
- P/E ratio of 11.61, indicating a potentially undervalued stock relative to its earnings.
- Profit margin of 13.6%, showcasing the company's ability to generate profits from its sales.
- Gross margin of 63.4%, highlighting efficient cost management in production and sales.
- Dividend yield of 7.25%, providing a substantial income stream for investors.
Wettbewerber & Vergleichsunternehmen
Staerken
- Strong brand recognition in China.
- Extensive distribution network.
- Diverse product portfolio.
- Established research and development capabilities.
Schwaechen
- Heavy reliance on the Chinese market.
- Vulnerability to regulatory changes in China.
- Exposure to fluctuations in raw material costs.
- Limited international presence.
Katalysatoren
- Ongoing: Expansion into new geographic markets within China, particularly lower-tier cities, is expected to drive revenue growth.
- Ongoing: Product innovation and the introduction of premium infant milk formula products cater to evolving consumer preferences.
- Ongoing: Continued growth in e-commerce sales through platforms like Tmall and JD.com.
- Upcoming: Potential strategic partnerships or acquisitions to expand product portfolio and market reach.
- Upcoming: Regulatory approvals for new product formulations or market expansions.
Risiken
- Ongoing: Intense competition from both domestic and international brands in the Chinese infant milk formula market.
- Ongoing: Regulatory changes in China's infant milk formula industry could impact production and sales.
- Potential: Fluctuations in raw material costs, such as milk powder and other ingredients, could affect profitability.
- Potential: Food safety concerns and negative publicity could damage brand reputation and consumer trust.
- Potential: Economic slowdown in China could reduce consumer spending on infant milk formula.
Wachstumschancen
- Expansion into Lower-Tier Cities: China Feihe has the opportunity to further penetrate lower-tier cities in China, where demand for infant milk formula is growing rapidly. These markets often have less competition from international brands, allowing Feihe to gain market share. By leveraging its existing distribution network and tailoring products to local preferences, Feihe can tap into this significant growth potential. The market size for infant milk formula in lower-tier cities is estimated to be substantial, with ongoing growth expected through 2030.
- Product Innovation and Premiumization: The company can drive growth by introducing new and innovative products, particularly in the premium segment. Chinese consumers are increasingly willing to pay more for high-quality and safe infant milk formula. Feihe can invest in research and development to create products with enhanced nutritional benefits and unique formulations. The premium infant milk formula market is projected to continue its expansion, offering significant revenue opportunities for Feihe.
- E-commerce Channel Expansion: China Feihe can further expand its presence on e-commerce platforms such as Tmall, JD.com, and its own online channels. Online sales of infant milk formula are growing rapidly in China, driven by convenience and accessibility. By optimizing its online marketing strategies and improving its online customer service, Feihe can capture a larger share of the online market. This channel offers a direct-to-consumer approach, enhancing brand engagement and customer loyalty.
- International Market Expansion: While primarily focused on the Chinese market, China Feihe has the potential to expand its presence in other international markets, particularly in Southeast Asia and other regions with significant Chinese diaspora populations. By adapting its products to local tastes and regulations, Feihe can tap into new sources of revenue and diversify its geographic risk. The global infant milk formula market is substantial, offering long-term growth opportunities for Feihe.
- Strategic Partnerships and Acquisitions: China Feihe can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its distribution network, and gain access to new technologies. Collaborating with other companies in the food and beverage industry can provide synergies and accelerate growth. Acquisitions can also help Feihe to consolidate its market position and gain access to new markets or product categories. These strategic moves can strengthen Feihe's competitive advantage and drive long-term value creation.
Chancen
- Expansion into lower-tier cities in China.
- Product innovation and premiumization.
- E-commerce channel expansion.
- International market expansion.
Risiken
- Intense competition from domestic and international brands.
- Changing consumer preferences.
- Food safety concerns.
- Economic slowdown in China.
Wettbewerbsvorteile
- Established brand reputation in the Chinese infant milk formula market.
- Extensive distribution network across online and offline channels.
- Strong research and development capabilities for product innovation.
- Scale of operations providing cost advantages.
Ueber CFEIY
Founded in 1962 and headquartered in Beijing, China Feihe Limited has grown to become a prominent player in the Chinese infant milk formula market. The company's core business revolves around the production and sale of infant milk formula products, catering primarily to the Mainland China market, with some presence in the United States. Over the years, China Feihe has expanded its product portfolio to include a variety of milk-based products, such as raw milk, adult milk powders, and liquid milk products. Additionally, the company offers health care products, soybean powder, goat milk powder, and nutritional supplements, including vitamins, minerals, and herbs. China Feihe distributes its products through an extensive network comprising distributors, e-commerce platforms like Tmall, JD.com, and Suning.com, its own website and mobile application (including WeChat), and approximately 2,000 offline customers with 110,000 retail points of sale as of December 31, 2021. This multi-channel approach allows the company to reach a broad customer base across different demographics and geographic locations within China.
Was das Unternehmen tut
- Produces and sells infant milk formula products.
- Offers raw milk and adult milk powders.
- Manufactures liquid milk products.
- Provides health care products.
- Produces soybean powder and goat milk powder.
- Retails vitamins, minerals, herbs, and other nutritional supplements.
Geschaeftsmodell
- Manufactures and distributes infant milk formula and related products.
- Sells products through distributors, e-commerce platforms, and its own website and mobile application.
- Operates a distribution network of offline customers with numerous retail points of sale.
Branchenkontext
China Feihe operates within the competitive packaged foods industry, specifically focusing on the infant milk formula market in China. This market is characterized by increasing demand due to rising disposable incomes and urbanization. However, it is also subject to stringent regulations and intense competition from both domestic and international brands. The industry is experiencing a trend towards premiumization, with consumers increasingly seeking high-quality and safe products. China Feihe's established brand and distribution network position it to capitalize on these trends.
Wichtige Kunden
- Infants and young children requiring milk formula.
- Parents and caregivers seeking nutritional products for their children.
- Adults consuming milk powders and health supplements.
Finanzdaten
Chart & Info
China Feihe Limited (CFEIY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 21. Jan. 2020
-
Stocks That Hit 52-Week Highs On Thursday
· 16. Jan. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CFEIY.
Kursziele
Wall-Street-Kurszielanalyse fuer CFEIY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CFEIY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Youbin Leng
CEO
Youbin Leng is the CEO of China Feihe Limited, leading a workforce of 9,590 employees. His background includes extensive experience in the food and beverage industry, with a focus on dairy and nutritional products. He has held various leadership positions within China Feihe, contributing to the company's growth and expansion. His expertise spans across operations, marketing, and strategic planning.
Erfolgsbilanz: Under Youbin Leng's leadership, China Feihe has strengthened its market position in the Chinese infant milk formula industry. He has overseen the expansion of the company's product portfolio and the enhancement of its distribution network. Key milestones include increased market share and improved financial performance. He has also focused on strengthening the company's brand reputation and ensuring product quality and safety.
China Feihe Limited ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. CFEIY is traded as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the stricter requirements of listed exchanges. This allows U.S. investors to invest in China Feihe more easily.
- Heimatmarkt-Ticker: Hong Kong Stock Exchange (CFEI), China
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: CFEI
CFEIY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure, and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for limited liquidity, requiring increased due diligence.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volumes can lead to price volatility.
- Wider bid-ask spreads increase transaction costs.
- Potential for fraud or manipulation is higher on the OTC market.
- Regulatory oversight is less stringent compared to listed exchanges.
- Verify the company's registration and legal status.
- Obtain and review the latest financial statements, if available.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Established operating history in the Chinese infant milk formula market.
- Presence on major e-commerce platforms in China.
- Significant market capitalization.
- Dividend payments to shareholders.
- Audited financial statements (if available).
Haeufige Fragen zu CFEIY
What are the key factors to evaluate for CFEIY?
China Feihe Limited (CFEIY) currently holds an AI score of 50/100, indicating moderate score. Key strength: Strong brand recognition in China.. Primary risk to monitor: Ongoing: Intense competition from both domestic and international brands in the Chinese infant milk formula market.. This is not financial advice.
How frequently does CFEIY data refresh on this page?
CFEIY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CFEIY's recent stock price performance?
Recent price movement in China Feihe Limited (CFEIY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition in China.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CFEIY overvalued or undervalued right now?
Determining whether China Feihe Limited (CFEIY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CFEIY?
Before investing in China Feihe Limited (CFEIY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CFEIY to a portfolio?
Potential reasons to consider China Feihe Limited (CFEIY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong brand recognition in China.. Additionally: Extensive distribution network.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CFEIY?
Yes, most major brokerages offer fractional shares of China Feihe Limited (CFEIY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CFEIY's earnings and financial reports?
China Feihe Limited (CFEIY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CFEIY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited analyst coverage due to OTC listing.
- Financial data may not be as readily available as for listed companies.
- OTC stocks carry higher risks than exchange-listed stocks.